Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10793212 | 0.94 | CYP3A4 (0.32) | CYP3A4CA1 | |
| Iodide SCHEMBL1478055 | 0.92 | CA4 (0.32) | CYP3A4 | |
| SCHEMBL8872262 | 0.73 | CYP3A4 (0.34) | CYP3A4 | |
| SCHEMBL11322427 | 0.71 | — | — | |
| SCHEMBL45523 | 0.71 | — | — | |
| Zinc Ion SCHEMBL28700463 | 0.69 | CA1 (0.38) | CYP3A4CA1 | |
| SCHEMBL6380221 | 0.69 | ALDH1A1 (0.42) | CYP3A4 | |
| SCHEMBL3982446 | 0.69 | — | — | |
| SCHEMBL554253 | 0.69 | CYP3A4 (0.32) | CYP3A4 | |
| SCHEMBL18838304 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2875021-B1 | BETA AMINO ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | UNIV SAINT LOUIS (US) | 2017-08-23 | — | — | EP | disclosed |
| US-9085606-B2 | Beta amino acid derivatives as integrin antagonists | SAINT LOUIS UNIVERSITY (US) | 2015-07-21 | — | — | US | disclosed |
| EP-2875021-A1 | BETA AMINO ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | Saint Louis University (US) | 2015-05-27 | — | — | EP | disclosed |
| US-20140038910-A1 | Beta Amino Acid Derivatives as Integrin Antagonists | SAINT LOUIS UNIVERSITY (US) | 2014-02-06 | — | — | US | disclosed |
| WO-2014015054-A1 | BETA AMINO ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | SAINT LOUIS UNIVERSITY (US) | 2014-01-23 | — | — | WO | disclosed |
| US-20050020505-A1 | R-isomer of beta amino acid compounds as integrin receptor antagonists derivatives | PHARMACIA CORPORATION | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140038910-A1 | Beta Amino Acid Derivatives as Integrin Antagonists | ITGB2, ITGAL, ITGB1 | CYP3A4 4229/4885CA1 4602/4885 |
| US-20050020505-A1 | R-isomer of beta amino acid compounds as integrin receptor antagonists derivatives | ITGA5, ITGAL, ITGB5 | CYP3A4 2812/4885CA1 2207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.